pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Undisclosed · news · pharmadog
← back to Undisclosed
News mentioning Undisclosed
107
stories
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
1d
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
biospace
2d
Lilly signs $5.9B deal with Stipple to unlock oncology targets
fiercebiotech
2d
Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
biospace
2d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
2d
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
biospace
5d
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
biospace
6d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
6d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
8d
Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
biospace
9d
Update: Compass submits psilocybin depression drug for approval after stock wobbles
biospace
9d
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
biospace
9d
Spruce spins out preclinical endocrinology program into newly formed Adrenyx
fiercebiotech
14d
Cash-strapped Vivoryon regains China rights to kidney disease prospect from Simcere
fiercebiotech
14d
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
biospace
14d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
15d
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
fiercebiotech
15d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
15d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
16d
BioArctic left out in the cold as Novartis walks away from $800M neuro collab
fiercebiotech
20d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
20d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
21d
Biopharma cuts at manufacturing plants expected to affect 4,000+
biospace
21d
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
biospace
27d
Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
fiercebiotech
28d
Astellas links up with AI Proteins in $400M computational drug discovery deal
fiercebiotech
29d
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
29d
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
Oct 19, 26
Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep
biospace
← prev
page 1 of 4
next →